Press Releases

Press Releases

Date Title
11/28/18 Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 28, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker , Ph.D., chief scientific officer, will
11/09/18 Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Start of Norovirus Vaccine Trials Delayed to 1H 2019 Due to Manufacturing Issue SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today
10/04/18 New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone ® Strong β7 + plasmablasts response in Vaxart vaccinees was highly correlated with protection SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 4, 2018-- Vaxart, Inc.
08/09/18 Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update

SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Aug. 9, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a

07/12/18 Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously

06/27/18 Oral RSV Vaccine - Preclinical Data Published in Vaccine

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral

06/04/18 Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

Safety and tolerability profile comparable to placebo Primary efficacy endpoint not achieved - Positive trend in two important subgroups SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are

06/01/18 Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive

05/31/18 Vaxart to Present at ASM Microbe 2018

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., lead scientist of Vaxart , will

05/15/18 Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 15, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31,